FY2025 · ended Dec 31, 2025 · Revenue $44.52M, +17.6% YoY · Filed Mar 9, 2026
Cumberland Pharmaceuticals Inc. (CPIX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $44.5 million and a net loss of $2.8 million. Free cash flow was $4.8 million. As of Jun 30, 2026 it held $3.9 million in cash and investments and $4.7 million in total debt.
Revenue (TTM)
$39.90M
-5.2% vs year-ago TTM
Net income (TTM)
$-10.92M
-272.4% vs year-ago TTM
Operating cash flow (TTM)
$745,969
-89.5% vs year-ago TTM
Free cash flow (TTM)
$683,899
-90.3% vs year-ago TTM
EPS (TTM)
$-0.73
-262.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
14.96M
+7.1% vs prior year
Net cash
$-851,782
as of Jun 30, 2026
Operating margin
-7.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CPIX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TN
- Headquarters
- Nashville,, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1087294
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $35.0M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M |
| Diluted EPS | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 |
| Operating cash flow | $4.9M | -$612,186 | $6.1M | $8.5M | $6.3M |
| Free cash flow | $4.8M | -$678,647 | $5.8M | $8.4M | $6.2M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M |
| Stockholders' equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M |
| Cash and investments | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M |
| Total debt | $4.9M | $10.4M | $5.6M | $4.8M | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K/A |
Amended current report
Shareholder vote results
|
Sep 11, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 28, 2026 | Aug 28, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
All 1000 Cumberland Pharmaceuticals Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.